Stockreport

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

Kamada Ltd. - Ordinary Shares  (KMDA) 
Last kamada ltd. - ordinary shares earnings: 2/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: kamada.com/investors.php
PDF Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint  [Read more]